These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 7510495)

  • 1. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
    Del Favero A; Roila F; Tonato M
    Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research on antiemetics: an Italian model of success].
    Roila F
    Tumori; 1998; 84(1 Suppl):S3-11. PubMed ID: 9617377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chemotherapy-induced emesis: the state of the art.
    Roila F; Tonato M; Del Favero A
    Dig Dis; 1993; 11(6):343-53. PubMed ID: 8306491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
    Malik I; Moid I; Khan Z; Hussain M
    Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
    Ann Oncol; 1998 Aug; 9(8):811-9. PubMed ID: 9789602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
    Hesketh PJ
    Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetics revisited.
    Roila F; Del Favero A
    Curr Opin Oncol; 1997 Jul; 9(4):321-6. PubMed ID: 9251881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of chemotherapy-induced delayed emesis.
    Tavorath R; Hesketh PJ
    Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
    Tonato M; Roila F; Del Favero A; Ballatori E
    Support Care Cancer; 1994 May; 2(3):150-60. PubMed ID: 8032700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.